Details

Autor(en) / Beteiligte

• Rezvani, Andrew R.
• Norasetthada, Lalitha
• Gooley, Ted
• Sorror, Mohamed
• Bouvier, Michelle E.
• Sahebi, Firoozeh
• Agura, Edward
• Chauncey, Thomas
• Maziarz, Richard T.
• Maris, Michael
• Shizuru, Judith
• Bruno, Benedetto
• Bredeson, Christopher
• Lange, Thoralf
• Yeager, Andrew
• Sandmaier, Brenda M.
• Storb, Rainer F.
• Maloney, David G.

Titel

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

Ist Teil von

• British journal of haematology, 2008-11, Vol.143 (3), p.395-403

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Summary Patients with relapsed diffuse large B‐cell lymphoma (DLBCL) who have failed or are ineligible for autologous haematopoietic cell transplantation (HCT) have a poor prognosis. We examined the outcomes of non‐myeloablative allogeneic HCT in this setting. Thirty‐one patients with DLBCL and one patient with Burkitt lymphoma received allogeneic HCT following 2 Gy total body irradiation with or without fludarabine. Median age was 52 years. Twenty‐four patients (75%) had undergone prior autologous HCT. Disease status at HCT was complete response (14/32, 44%), partial response (9/32, 28%), or refractory (9/32, 28%). Cumulative incidences of acute graft‐versus‐host disease (GVHD) grades II–IV, grades III–IV, and chronic GVHD were 53%, 19%, and 47% respectively. With a median follow‐up of 45 months, 3‐year estimated overall (OS) and progression‐free survival (PFS) was 45% and 35% respectively. Three‐year cumulative incidences of relapse and non‐relapse mortality were 41% and 25% respectively. In multivariate models, chemosensitive disease and receipt of ≥4 lines of treatment before HCT were associated with better OS. Patients with chemosensitive disease had 3‐year OS and PFS of 56% and 43% respectively. Non‐myeloablative allogeneic HCT can produce long‐term disease‐free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT.